The regulatory enforcement environment in China remains tense, as both the Chinese government and media bring new actions and allegations against life sciences manufacturers in both the pharmaceutical and device sectors. We are seeing:

  • Increased attention to medical device sector 
  • Enforcement actions spreading to smaller cities 
  • Continued pressure on pharmaceutical sector 
  • Reports of misconduct by local manufacturers 
  • Questionable vendors named